NASDAQ Stock Exchange News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 984,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "7b6d2bd1-0e41-4bd9-b2a2-d0ed23ffd196",
"title": "Office towers out, campuses in",
"description": "As Mobileye inaugurates its NIS 1 billion Jerusalem campus,",
"keywords": "",
"snippet": "Mobileye - investment of more than NIS 1 billion\n\nMobileye Global Inc. (Nasdaq: MBLY) has invested more than NIS 1 billion in its new campus in Har Hotzvim in J...",
"url": "https://en.globes.co.il/en/article-office-towers-out-campuses-in-1001475029",
"image_url": "https://res.cloudinary.com/globes/image/upload/t_800X392/v1710763336/direct/%D7%A7%D7%9E%D7%A4%D7%95%D7%A1_%D7%93%D7%99%D7%A1%D7%A7%D7%95%D7%A0%D7%98_%D7%A6%D7%99%D7%9C%D7%95%D7%9D_%D7%90%D7%99%D7%9C_%D7%AA%D7%92%D7%A8_2_gqdh7c.jpg",
"language": "en",
"published_at": "2024-03-28T10:49:26.000000Z",
"source": "en.globes.co.il",
"relevance_score": null,
"entities": [
{
"symbol": "GAN",
"name": "GAN Limited",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 6.634065,
"sentiment_score": 0.128,
"highlights": [
{
"highlight": "The Israeli advanced driving assistance systems (ADAS) company has until now been based in another office building in Har Hotzvim and also has offices in Ramat <em>Gan</em> and elsewhere worldwide but it decided to build its new headquarters in Jerusalem and focus all its main functions there.",
"sentiment": 0.128,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "DOX",
"name": "Amdocs Limited",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 22.772924,
"sentiment_score": 0.28728,
"highlights": [
{
"highlight": "It's like Microsoft and <em>Amdocs</em>. Within the application you have the ability to report problems, order food, schedule meetings, use Teams. The idea was to make a technological leap.\"\n\n\"Our vision included flexible planning. We understood that anything that is not modular and receptive limits the ability to change in the future.",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Amdocs</em> - \"The aim wasn't to save but to do things right.\"\n\nThe campus of Israeli business software giant <em>Amdocs</em> Ltd. (<em>Nasdaq</em>: <em>DOX</em>) in the Ra'anana industrial zone has 65,000 square meters of offices on a 43 dunam (10.75 acres) site, for 3,000 employees.",
"sentiment": -0.0829,
"highlighted_in": "main_text"
},
{
"highlight": "The <em>Amdocs</em> campus is located on edge of the Ra'anana industrial zone, near Road 4, overlooking orchards and fields. It is built in a park and consists of four buildings, each of which has a high patio that lets light inside.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "\"Designed and built according to our values\"\n\n\"This is the only <em>Amdocs</em> building in the world that we own,\" says <em>Amdocs</em> director global services EMEA Galit Falach-Stanyetzky. \"It was designed and built according to our values, so that it would not be too closed and oppressive nor too excessive.",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Amdocs</em> personnel and especially the previous CEO Eli Gelman were deeply involved in the planning, in every detail. It was not a 'launch and forget' project.\"\n\nA second building with a separate entrance was designed in case the company needs to expand, and is currently leased to the Mixer chain.",
"sentiment": 0.3744,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MSFT",
"name": "Microsoft Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 5.29241,
"sentiment_score": 0.743,
"highlights": [
{
"highlight": "It's like <em>Microsoft</em> and Amdocs. Within the application you have the ability to report problems, order food, schedule meetings, use Teams. The idea was to make a technological leap.\"\n\n\"Our vision included flexible planning. We understood that anything that is not modular and receptive limits the ability to change in the future.",
"sentiment": 0.743,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "9c372dbd-cc3d-4563-bb91-e46a07727756",
"title": "Rex American Resources shares jump 4% on earnings beat By Investing.com",
"description": "Rex American Resources shares jump 4% on earnings beat",
"keywords": "",
"snippet": "DAYTON, Ohio - REX American Resources (NASDAQ: ) Corporation (NYSE:REX), a leader in ethanol production, reported a significant earnings beat for the fourth qua...",
"url": "https://www.investing.com/news/company-news/rex-american-resources-shares-jump-4-on-earnings-beat-93CH-3356450",
"image_url": "https://i-invdn-com.investing.com/news/news_six_pile_69x52._800x533_L_1419494215.jpg",
"language": "en",
"published_at": "2024-03-28T10:46:19.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "AREC",
"name": "American Resources Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Energy",
"match_score": 49.898342,
"sentiment_score": 0.2516,
"highlights": [
{
"highlight": "DAYTON, Ohio - REX <em>American</em> <em>Resources</em> (NASDAQ: ) Corporation (NYSE:REX), a leader in ethanol production, reported a significant earnings beat for the fourth quarter, with a net income per share of $1.16, outpacing analyst expectations by $0.48.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "For the fourth quarter of fiscal year 2023, REX <em>American</em> <em>Resources</em> saw a decrease in net sales and revenue by approximately 6% YoY, from $200.2 million in Q4 2022 to $187.6 million in the same period for 2023.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Rex <em>American</em> <em>Resources</em> shares jump 4% on earnings beat By Investing.com",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "ecdc97a2-cefc-4150-865b-a0b869b4ebec",
"title": "Nutrex-Hawaii Introduces Its #1 Selling BioAstin ® Hawaiian Astaxanthin ® in a Retail-Ready, Sugar-Free, Vegan Gummy Format By Investing.com",
"description": "Nutrex-Hawaii Introduces Its #1 Selling BioAstin ® Hawaiian Astaxanthin ® in a Retail-Ready, Sugar-Free, Vegan Gummy Format",
"keywords": "",
"snippet": "The new gummy offers an industry-leading 12mg of Hawaiian Astaxanthin ® per serving “ 6000 times the antioxidant power of Vitamin C “ with science-backed, ...",
"url": "https://www.investing.com/news/press-releases/nutrexhawaii-introduces-its-1-selling-bioastin--hawaiian-astaxanthin--in-a-retailready-sugarfree-vegan-gummy-format-93CH-3356373",
"image_url": "https://i-invdn-com.investing.com/news/news_six_pile_69x52._800x533_L_1419494215.jpg",
"language": "en",
"published_at": "2024-03-28T10:16:08.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "CYAN",
"name": "Cyanotech Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 50.27028,
"sentiment_score": 0.494933,
"highlights": [
{
"highlight": "., a wholly owned subsidiary of <em>Cyanotech</em> <em>Corporation</em>, unveils its #1 selling BioAstin ® Hawaiian Astaxanthin ® dietary supplement in a groundbreaking sugar free gummy format, enriched with an industry-leading 12mg of natural Hawaiian Astaxanthin per daily serving.",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "About Nutrex-Hawaii, Inc.: Nutrex-Hawaii, a wholly owned subsidiary of <em>Cyanotech</em> <em>Corporation</em>, is the global leader in natural, premium microalgae dietary supplements for health and wellness, leading the natural channel category with its BioAstin ® Hawaiian Astaxanthin ® and Hawaiian Spirulina Pacifica ® brands.",
"sentiment": 0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "View source version on businesswire.com: https://www.businesswire.com/news/home/20240328602781/en/\n\nFelicia Ladin\n\n(808) 334-9455\n\[email protected]\n\nSource: <em>Cyanotech</em> <em>Corporation</em>",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "7fe4bd45-b69f-4ce6-8e32-8a46ce2466c0",
"title": "Nutrex-Hawaii Introduces Its #1 Selling BioAstin® Hawaiian Astaxanthin® in a Retail-Ready, Sugar-Free, Vegan Gummy Format",
"description": "The new gummy offers an industry-leading 12mg of Hawaiian Astaxanthin® per serving – 6000 times the antioxidant power of Vitamin C – with science-backed, multifunctional benefits and a 40-year...",
"keywords": "Markets",
"snippet": "The new gummy offers an industry-leading 12mg of Hawaiian Astaxanthin® per serving – 6000 times the antioxidant power of Vitamin C – with science-backed, m...",
"url": "https://www.marketscreener.com/quote/stock/CYANOTECH-CORPORATION-8984/news/Nutrex-Hawaii-Introduces-Its-1-Selling-BioAstin-Hawaiian-Astaxanthin-in-a-Retail-Ready-Sugar-F-46308341/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-03-28T10:06:05.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "CYAN",
"name": "Cyanotech Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 38.77826,
"sentiment_score": 0.7424,
"highlights": [
{
"highlight": "., a wholly owned subsidiary of <em>Cyanotech</em> <em>Corporation</em>, unveils its #1 selling BioAstin® Hawaiian Astaxanthin® dietary supplement in a groundbreaking sugar free gummy format, enriched with an industry-leading 12mg of natural Hawaiian Astaxanthin per daily serving.",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "About Nutrex-Hawaii, Inc.: Nutrex-Hawaii, a wholly owned subsidiary of <em>Cyanotech</em> <em>Corporation</em>, is the global leader in natural, premium microalgae dietary supplements for health and wellness, leading the natural channel category with its BioAstin® Hawaiian Astaxanthin® and Hawaiian Spirulina Pacifica® brands.",
"sentiment": 0.7845,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "8b1ae3cb-e2ba-4ec7-86fd-9a1300be2eba",
"title": "Mannatech Incorporated : Reports Financial Results for Fourth Quarter and Full Year 2023 - Form 8-K -March 28, 2024 at 06:06 am EDT",
"description": "Mannatech Reports Financial Results for Fourth Quarter and Full Year 2023\n \n \n \n \n \n FLOWER MOUND, Texas, March 28, 2024 - Mannatech, Incorporated, a global health and...",
"keywords": "Markets",
"snippet": "Mannatech Reports Financial Results for Fourth Quarter and Full Year 2023\n\n\n\n\n\nFLOWER MOUND, Texas, March 28, 2024 - Mannatech, Incorporated(NASDAQ: MTEX), a gl...",
"url": "https://www.marketscreener.com/quote/stock/MANNATECH-INCORPORATED-9826308/news/Mannatech-Incorporated-Reports-Financial-Results-for-Fourth-Quarter-and-Full-Year-2023-Form-8-K-46308352/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-03-28T10:06:28.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "MTEX",
"name": "Mannatech, Incorporated",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 107.61637,
"sentiment_score": 0.40174,
"highlights": [
{
"highlight": "Mannatech Reports Financial Results for Fourth Quarter and Full Year 2023\n\n\n\n\n\nFLOWER MOUND, Texas, March 28, 2024 - <em>Mannatech</em>, <em>Incorporated</em>(<em>NASDAQ</em>: <em>MTEX</em>), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter and year ended December 31, 2023.",
"sentiment": 0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "Barta\n\nGeneral Counsel and Corporate Secretary\n\n972-471-7742\n\[email protected]\n\nwww.mannatech.com\n\n\n\n\n\n\n\n\n\n\n\n\n\n<em>MANNATECH</em>, <em>INCORPORATED</em> AND SUBSIDIARIES\n\nCONSOLIDATED BALANCE SHEETS\n\n(in thousands, except share information)\n\nDecember 31, 2023 December 31, 2022 ASSETS Cash and cash equivalents $ 7,731 $ 13,777 Restricted cash 938 944 Accounts receivable",
"sentiment": 0.2577,
"highlighted_in": "main_text"
},
{
"highlight": "Retained earnings (accumulated deficit) (1,301) 1,686 Accumulated other comprehensive (loss) (1,015) (208) Treasury stock, at average cost, 882,703 shares as of December 31, 2023 and 884,057 shares as of December 31, 2022 (20,509) (20,679) Total shareholders' equity 10,484 14,176 Total liabilities and shareholders' equity $ 41,206 $ 49,128\n\n\n\n\n\n\n\n\n\n<em>MANNATECH</em>",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": ", <em>INCORPORATED</em> AND SUBSIDIARIES\n\nCONSOLIDATED STATEMENTS OF OPERATIONS\n\n(in thousands, except per share information)\n\nFor the three months ended December 31 For the years ended December 31 2023 2022 2023 2022 $000 % $000 % $000 % $000 % Net sales $ 32,694 100.0 % $ 34,335 100.0 % $ 131,955 100.0 % $ 137,208 100.0 % Cost of sales 8,048 24.6 10,633 31.0",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Mannatech</em> <em>Incorporated</em> : Reports Financial Results for Fourth Quarter and Full Year 2023 - Form 8-K -March 28, 2024 at 06:06 am EDT",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "0dad2318-f1a6-41eb-ab91-eb3875e04951",
"title": "Cheche Group Reports Fourth Quarter and Full Year 2023 Unaudited Financial Results",
"description": "BEIJING, March 28, 2024 /PRNewswire/ -- Cheche Group Inc. , China's leading auto insurance technology platform, today announced its unaudited financial results for the fourth quarter and full...",
"keywords": "Markets",
"snippet": "BEIJING, March 28, 2024 /PRNewswire/ -- Cheche Group Inc. (NASDAQ: CCG) (\"Cheche\", \"the Company\" or \"we\"), China's leading auto insurance technology platform, t...",
"url": "https://www.marketscreener.com/quote/stock/CHECHE-GROUP-INC-114463435/news/Cheche-Group-Reports-Fourth-Quarter-and-Full-Year-2023-Unaudited-Financial-Results-46308216/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-03-28T10:01:10.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "FANH",
"name": "Fanhua Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 7.44849,
"sentiment_score": 0.69475,
"highlights": [
{
"highlight": "(previously named <em>Fanhua</em> Times Sales and Service Co., Ltd), change in fair value of warrants, and listing related professional service fees. Adjusted net loss per share, basic and diluted, is calculated as adjusted net loss divided by weighted-average ordinary shares outstanding.",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "(previously named <em>Fanhua</em> Times Sales and Service Co., Ltd), change in fair value of warrants, and listing related professional service fees.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PIAI",
"name": "Prime Impact Acquisition I",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 13.540421,
"sentiment_score": 0.24695,
"highlights": [
{
"highlight": "On September 14, 2023 , the Company successfully closed its business combination with <em>Prime</em> <em>Impact</em> <em>Acquisition</em> <em>I</em>. Cheche began trading on the Nasdaq Stock Market on September 18, 2023 .\n\n, the Company with <em>Prime</em> <em>Impact</em> <em>Acquisition</em> <em>I</em>. Cheche began trading on the Nasdaq Stock Market on .",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "Business Combination\n\nOn September 14, 2023 (the \"Closing Date\"), the Company completed the previously announced business combination (the \"Business Combination\") with <em>Prime</em> <em>Impact</em> <em>Acquisition</em> <em>I</em> (\"Prime Impact\"). Cheche began trading on the Nasdaq Stock Exchange on September 18, 2023.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PIAI-UN",
"name": "Prime Impact Acquisition I",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 13.540421,
"sentiment_score": 0.24695,
"highlights": [
{
"highlight": "On September 14, 2023 , the Company successfully closed its business combination with <em>Prime</em> <em>Impact</em> <em>Acquisition</em> <em>I</em>. Cheche began trading on the Nasdaq Stock Market on September 18, 2023 .\n\n, the Company with <em>Prime</em> <em>Impact</em> <em>Acquisition</em> <em>I</em>. Cheche began trading on the Nasdaq Stock Market on .",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "Business Combination\n\nOn September 14, 2023 (the \"Closing Date\"), the Company completed the previously announced business combination (the \"Business Combination\") with <em>Prime</em> <em>Impact</em> <em>Acquisition</em> <em>I</em> (\"Prime Impact\"). Cheche began trading on the Nasdaq Stock Exchange on September 18, 2023.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PIAI-WT",
"name": "Prime Impact Acquisition I",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 13.540524,
"sentiment_score": 0.24695,
"highlights": [
{
"highlight": "On September 14, 2023 , the Company successfully closed its business combination with <em>Prime</em> <em>Impact</em> <em>Acquisition</em> <em>I</em>. Cheche began trading on the Nasdaq Stock Market on September 18, 2023 .\n\n, the Company with <em>Prime</em> <em>Impact</em> <em>Acquisition</em> <em>I</em>. Cheche began trading on the Nasdaq Stock Market on .",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "Business Combination\n\nOn September 14, 2023 (the \"Closing Date\"), the Company completed the previously announced business combination (the \"Business Combination\") with <em>Prime</em> <em>Impact</em> <em>Acquisition</em> <em>I</em> (\"Prime Impact\"). Cheche began trading on the Nasdaq Stock Exchange on September 18, 2023.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "5bc503a6-bbfb-4f05-9a00-3c64d7ab1ddb",
"title": "36Kr Holdings Inc. Reports Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results By Investing.com",
"description": "36Kr Holdings Inc. Reports Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results",
"keywords": "",
"snippet": "BEIJING , March 28, 2024 /PRNewswire/ -- 36Kr Holdings Inc (NASDAQ: ). (\"36Kr\" or the \"Company\" or \"We\") (NASDAQ: KRKR), a prominent brand and a pioneering plat...",
"url": "https://www.investing.com/news/press-releases/36kr-holdings-inc-reports-fourth-quarter-and-fiscal-year-2023-unaudited-financial-results-93CH-3356271",
"image_url": "https://i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg",
"language": "en",
"published_at": "2024-03-28T09:12:08.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "KRKR",
"name": "36Kr Holdings Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 129.7187,
"sentiment_score": 0.108109,
"highlights": [
{
"highlight": "BEIJING , March 28, 2024 /PRNewswire/ -- <em>36Kr</em> <em>Holdings</em> <em>Inc</em> (NASDAQ: ). (\"36Kr\" or the \"Company\" or \"We\") (<em>NASDAQ</em>: <em>KRKR</em>), a prominent brand and a pioneering platform dedicated to serving New Economy participants in China , today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023 .",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "Net loss attributable to <em>36Kr</em> <em>Holdings</em> <em>Inc</em>.'s ordinary shareholders was RMB18.8 million ( US$2.6 million ) in the fourth quarter of 2023, compared to net loss attributable to <em>36Kr</em> <em>Holdings</em> <em>Inc</em>.'s ordinary shareholders of RMB20.8 million in the same period of 2022.",
"sentiment": -0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "Net loss attributable to <em>36Kr</em> <em>Holdings</em> <em>Inc</em>.'s ordinary shareholders was RMB90.0 million ( US$12.7 million ) in fiscal year 2023, compared to net income attributable to <em>36Kr</em> <em>Holdings</em> <em>Inc</em>.'s ordinary shareholders of RMB21.9 million in the prior year.",
"sentiment": -0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "A replay of the conference call will be available for one week from the date of the conference, by dialing the following telephone numbers:\n\nUnited States : +1-855-883-1031 International: +61-7-3107-6325 Hong Kong , China : 800-930-639 Mainland China : 400-120-9216 Replay PIN: 10037774\n\nAbout <em>36Kr</em> <em>Holdings</em> <em>Inc</em>.\n\n<em>36Kr</em> <em>Holdings</em> <em>Inc</em>. is a prominent brand",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "For investor and media inquiries, please contact:\n\nIn China :\n\n<em>36Kr</em> <em>Holdings</em> <em>Inc</em>.",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Investor Relations\n\nTel: +86 (10) 8965-0708\n\nE-mail: [email protected]\n\nPiacente Financial Communications\n\nJenny Cai\n\nTel: +86 (10) 6508-0677\n\nE-mail: [email protected]\n\nIn the United States :\n\nPiacente Financial Communications\n\nBrandi Piacente\n\nTel: +1-212-481-2050\n\nE-mail: [email protected]\n\n<em>36Kr</em> <em>Holdings</em> <em>Inc</em>.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Holdings</em> <em>Inc</em>.'",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "s shareholders' equity 338,106\n\n251,977\n\n35,491 Non-controlling interests 7,278\n\n9,883\n\n1,392 Total shareholders' equity 345,384\n\n261,860\n\n36,883 Total liabilities and shareholders' equity 571,371\n\n458,966\n\n64,646\n\n\n\n\n\n\n\n\n\n\n\n\n\n<em>36Kr</em> <em>Holdings</em> <em>Inc</em>.",
"sentiment": 0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Holdings</em> <em>Inc</em>.'",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Holdings</em> <em>Inc</em>.'",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>36Kr</em> <em>Holdings</em> <em>Inc</em>. Reports Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "BILI",
"name": "Bilibili Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 6.063933,
"sentiment_score": 0.1768,
"highlights": [
{
"highlight": "[1] \"Number of followers\" refers to the aggregate number of followers across the official accounts we own and/or operate on various social media and online platforms, including but not limited to Weixin, Weibo (NASDAQ: ), Zhihu, Toutiao, Xinhua Net , Douyin and <em>Bilibili</em> (NASDAQ: ).",
"sentiment": 0.1768,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "WB",
"name": "Weibo Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 5.694181,
"sentiment_score": 0.1768,
"highlights": [
{
"highlight": "[1] \"Number of followers\" refers to the aggregate number of followers across the official accounts we own and/or operate on various social media and online platforms, including but not limited to Weixin, <em>Weibo</em> (NASDAQ: ), Zhihu, Toutiao, Xinhua Net , Douyin and Bilibili (NASDAQ: ).",
"sentiment": 0.1768,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "94b2ff67-4a43-491b-b5b8-07447716c424",
"title": "Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer",
"description": "Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early\n\n...",
"keywords": "Markets",
"snippet": "Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early\n\nEx...",
"url": "https://www.marketscreener.com/quote/stock/EXACT-SCIENCES-CORPORATIO-9232/news/Exact-Sciences-Advances-Development-of-Non-Endoscopic-Oncoguard-Esophagus-Test-to-Screen-for-Esoph-46308282/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-03-28T10:04:10.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "EXAS",
"name": "Exact Sciences Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 72.24073,
"sentiment_score": -0.07301,
"highlights": [
{
"highlight": "Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early\n\n<em>Exact</em> <em>Sciences</em> Corp.",
"sentiment": -0.8773,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>Nasdaq</em>: <em>EXAS</em>), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Comprehensive Cancer Center, reported on data showing high sensitivity and specificity for the non-endoscopic Oncoguard® Esophagus test that is currently in development for the detection of esophageal adenocarcinoma (EAC) and its precursors",
"sentiment": -0.8316,
"highlighted_in": "main_text"
},
{
"highlight": "“In collaborating with <em>Exact</em> <em>Sciences</em>, we are able to study the potential of a minimally invasive, non-endoscopic screening tool currently in development in patients at higher risk for EAC. Our algorithm training and testing study accomplishes the next critical step for the accurate, non-endoscopic detection of BE/EAC.”",
"sentiment": -0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "While many experts recommend that people with chronic reflux disease and at least one other risk factor be screened for Barrett’s esophagus, only a small number of eligible patients undergo screening currently,”8 said Paul Limburg, Chief Medical Officer of Screening, <em>Exact</em> <em>Sciences</em>.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "“At <em>Exact</em> <em>Sciences</em>, our work has always focused on the latest innovations in screening and testing to help patients and clinicians have accurate, less invasive, and cost-effective options.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Exact</em> <em>Sciences</em> Corp.\n\nA leading provider of cancer screening and diagnostic tests, <em>Exact</em> <em>Sciences</em> gives patients and health care professionals the clarity needed to take life-changing action earlier.",
"sentiment": 0.128,
"highlighted_in": "main_text"
},
{
"highlight": "Building on the success of the Cologuard® and Oncotype® tests, <em>Exact</em> <em>Sciences</em> is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "For more information, visit ExactSciences.com, follow <em>Exact</em> <em>Sciences</em> on X (formerly known as Twitter) @ExactSciences, or find <em>Exact</em> <em>Sciences</em> on LinkedIn and Facebook.\n\nNOTE: <em>Exact</em> <em>Sciences</em>, Cologuard and Oncoguard are trademarks or registered trademarks of <em>Exact</em> <em>Sciences</em> <em>Corporation</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "., a wholly-owned subsidiary of <em>Exact</em> <em>Sciences</em> <em>Corporation</em>. All other trademarks and service marks are the property of their respective owners.\n\nForward-Looking Statement\n\nThis news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Exact</em> <em>Sciences</em> Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer",
"sentiment": -0.6597,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "69c202ee-e689-4235-b003-eab52a4cdba8",
"title": "Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors",
"description": "VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse…",
"keywords": "",
"snippet": "This advertisement has not loaded yet, but your article continues below.\n\nZymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors\n\nArtic...",
"url": "https://financialpost.com/globe-newswire/zymeworks-announces-appointment-of-dr-neil-gallagher-to-its-board-of-directors",
"image_url": "https://dcs-static.gprod.postmedia.digital/15.7.3/websites/images/fp/favicon-fp.ico",
"language": "en",
"published_at": "2024-03-28T10:04:09.000000Z",
"source": "financialpost.com",
"relevance_score": null,
"entities": [
{
"symbol": "AZN",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 8.030201,
"sentiment_score": -0.2023,
"highlights": [
{
"highlight": "Before joining Amgen, he spent 10 years at Novartis in both Europe and the United States, and also held roles at Astex Therapeutics and <em>AstraZeneca</em>. He received an M.D. from Trinity College Dublin and a Ph.D. in Cancer Biology from the University of Birmingham.\n\nTop Stories Get the latest headlines, breaking news and columns.",
"sentiment": -0.2023,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AMGN",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.314741,
"sentiment_score": 0.4215,
"highlights": [
{
"highlight": "He has also served as Vice President and Head, Global Oncology Development at AbbVie and Head of Development, Oncology, and Inflammation at <em>Amgen</em>. Before joining <em>Amgen</em>, he spent 10 years at Novartis in both Europe and the United States, and also held roles at Astex Therapeutics and AstraZeneca.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BGNE",
"name": "BeiGene, Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 20.446102,
"sentiment_score": 0.4588,
"highlights": [
{
"highlight": "Zymeworks has entered into separate agreements with <em>BeiGene</em>, <em>Ltd</em>. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "SNDX",
"name": "Syndax Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 27.341185,
"sentiment_score": -0.1591,
"highlights": [
{
"highlight": "Gallagher currently serves as President and Head, Research & Development at <em>Syndax</em> <em>Pharmaceuticals</em> (<em>Nasdaq</em>: <em>SNDX</em>). As a physician-scientist, trained gynecological oncologist, and research scientist working in cancer biology, he has extensive drug development experience from late pre-clinical to translational research and marketing approval. Dr.",
"sentiment": -0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Before joining <em>Syndax</em> <em>Pharmaceuticals</em> in 2023, Dr. Gallagher was Head of Development and Chief Medical Officer of AbbVie. He has also served as Vice President and Head, Global Oncology Development at AbbVie and Head of Development, Oncology, and Inflammation at Amgen.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "JAZZ",
"name": "Jazz Pharmaceuticals plc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.680017,
"sentiment_score": 0.2263,
"highlights": [
{
"highlight": "(BeiGene) and <em>Jazz</em> <em>Pharmaceuticals</em> Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers.",
"sentiment": 0.2263,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "7236c445-dfd8-441d-91a2-4dde198e7ce3",
"title": "China Automotive Systems GAAP EPS of $0.36, revenue of $159.2M (NASDAQ:CAAS)",
"description": "China Automotive Systems reports record annual revenue and 81.2% increase in diluted EPS for Q4.",
"keywords": "",
"snippet": "To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.\n\nIf you have an ad-blocker enabled you may be blocked from ...",
"url": "https://seekingalpha.com/news/4084771-china-automotive-systems-gaap-eps-of-0_36-revenue-of-159_2m",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-03-28T10:04:06.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "CAAS",
"name": "China Automotive Systems, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 111.11476,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>China</em> <em>Automotive</em> <em>Systems</em> GAAP EPS of $0.36, revenue of $159.2M (<em>NASDAQ:CAAS</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "27e0a2ad-539a-4a18-a145-0466b65a5e75",
"title": "REX American Resources Reports Full Fiscal Year 2023 Net Income Per Share Attributable to REX Common Shareholders of $3.47, the Second Highest in Company History",
"description": "Generated $1.16 and $3.47 of net income per share in Q4 and Full Fiscal Year ‘23, respectively; Full Fiscal Year net income per share was the second highest in company history\n\n\n\nReported gross...",
"keywords": "Markets",
"snippet": "Generated $1.16 and $3.47 of net income per share in Q4 and Full Fiscal Year ‘23, respectively; Full Fiscal Year net income per share was the second highest i...",
"url": "https://www.marketscreener.com/quote/stock/REX-AMERICAN-RESOURCES-CO-14294/news/REX-American-Resources-Reports-Full-Fiscal-Year-2023-Net-Income-Per-Share-Attributable-to-REX-Common-46308271/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-03-28T10:03:06.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "AREC",
"name": "American Resources Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Energy",
"match_score": 46.54196,
"sentiment_score": 0.38431,
"highlights": [
{
"highlight": "gallons and 285.9 million gallons for Q4 and Full Fiscal Year ’23, respectively, an increase of approximately 13% and 8% over each of the respective periods for 2022 Commenced site construction on the One Earth Energy carbon capture facility at the Gibson City, Illinois facility during Q3; expect completion of the compression facility during Q2 ‘24\n\nREX <em>American</em>",
"sentiment": 0.8225,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Resources</em> <em>Corporation</em> (“REX” or the “Company”) (NYSE: REX), a leading ethanol production company, today announced financial and operational results for the Company’s full year and fiscal fourth quarter 2023.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "REX <em>American</em> <em>Resources</em>’ Q4 and full fiscal year 2023 results principally reflect its interests in six ethanol production facilities.",
"sentiment": 0.25,
"highlighted_in": "main_text"
},
{
"highlight": "About REX <em>American</em> <em>Resources</em> <em>Corporation</em>\n\nREX <em>American</em> <em>Resources</em> <em>Corporation</em> has interests in six ethanol production facilities, which in aggregate have production capacity totaling approximately 730 million gallons per year. REX’s effective ownership of annual volumes is approximately 300 million gallons.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "REX <em>AMERICAN</em> <em>RESOURCES</em> <em>CORPORATION</em> AND SUBSIDIARIES Consolidated Statements of Operations (in thousands, except per share amounts) Unaudited Three Months Ended Year Ended January 31, January 31, 2024 2023 2024 2023 Net sales and revenue $ 187,614 $ 200,167 $ 833,384 $ 855,000 Cost of sales 157,204 186,849 735,166 806,398 Gross profit 30,410 13,318 98,218",
"sentiment": 0.25,
"highlighted_in": "main_text"
},
{
"highlight": "27,697 Weighted average shares outstanding – basic 17,548 17,416 17,482 17,638 Basic net income per share attributable to REX common shareholders $ 1.17 $ 0.47 $ 3.49 $ 1.57 Weighted average shares outstanding – diluted 17,657 17,416 17,576 17,638 Diluted net income per share attributable to REX common shareholders $ 1.16 $ 0.47 $ 3.47 $ 1.57\n\nREX <em>AMERICAN</em>",
"sentiment": 0.9413,
"highlighted_in": "main_text"
},
{
"highlight": "<em>RESOURCES</em> <em>CORPORATION</em> AND SUBSIDIARIES Consolidated Balance Sheets (in thousands) Unaudited January 31, January 31, 2024 2023 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 223,397 $ 69,612 Short-term investments 155,260 211,331 Restricted cash - 1,735 Accounts receivable 23,185 25,162 Inventory 26,984 48,744 Refundable income taxes 5,728 2,962",
"sentiment": 0.3107,
"highlighted_in": "main_text"
},
{
"highlight": "long-term liabilities 10,946 13,986 EQUITY: REX shareholders’ equity: Common stock 299 299 Paid-in capital 3,769 578 Retained earnings 701,761 640,826 Treasury stock (191,911) (193,721) Total REX shareholders’ equity 513,918 447,982 Noncontrolling interests 73,679 63,012 Total equity 587,597 510,994 TOTAL LIABILITIES AND EQUITY $ 664,802 $ 579,579\n\nREX <em>AMERICAN</em>",
"sentiment": -0.1111,
"highlighted_in": "main_text"
},
{
"highlight": "<em>RESOURCES</em> <em>CORPORATION</em> AND SUBSIDIARIES Consolidated Statements of Cash Flows (in thousands) Unaudited Year Ended January 31, January 31, 2024 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Net Income including noncontrolling interest $ 75,924 $ 37,937 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation 17,794",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "REX <em>American</em> <em>Resources</em> Reports Full Fiscal Year 2023 Net Income Per Share Attributable to REX Common Shareholders of $3.47, the Second Highest in Company History",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "7918027f-95a7-4ac8-a8e8-2b51effb6d86",
"title": "Goldman Sachs réaffirme son opinion d'achat sur l'action Moderna, citant l'accord avec Blackstone Par Investing.com",
"description": "Goldman Sachs réaffirme son opinion d'achat sur l'action Moderna, citant l'accord avec Blackstone",
"keywords": "",
"snippet": "Jeudi, Goldman Sachs a réaffirmé sa note d'achat sur l'action Moderna, en maintenant l'objectif de prix à 206,00 $. Moderna, cotée au NASDAQ:MRNA, a récemm...",
"url": "https://fr.investing.com/news/company-news/goldman-sachs-reaffirme-son-opinion-dachat-sur-laction-moderna-citant-laccord-avec-blackstone-93CH-2356115",
"image_url": "https://i-invdn-com.investing.com/news/Moderna_800x533_L_1598373015.jpg",
"language": "fr",
"published_at": "2024-03-28T10:02:11.000000Z",
"source": "fr.investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 33.298656,
"sentiment_score": null,
"highlights": [
{
"highlight": "Jeudi, Goldman Sachs a réaffirmé sa note d'achat sur l'action <em>Moderna</em>, en maintenant l'objectif de prix à 206,00 $. <em>Moderna</em>, cotée au <em>NASDAQ:MRNA</em>, a récemment tenu son cinquième Vaccines Day, au cours duquel plusieurs mises à jour importantes ont été partagées.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Outre le partenariat avec Blackstone, <em>Moderna</em> a fait état de données cliniques positives concernant trois vaccins candidats qui entrent dans la phase 3 des essais : Le virus d'Epstein-Barr, le virus de la varicelle et du zona et le norovirus.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> a également fourni des informations sur son vaccin COVID-19 de nouvelle génération, conçu pour être stable au réfrigérateur.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Goldman Sachs a exprimé des perspectives positives pour le lancement du vaccin contre le VRS de <em>Moderna</em>, qui devrait faire l'objet d'une décision de la PDUFA le 12 mai. Le format de seringue pré-remplie du vaccin est considéré comme un avantage concurrentiel.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Perspectives InvestingPro\n\nAlors que <em>Moderna</em> continue de faire progresser son portefeuille de vaccins, les données en temps réel d'InvestingPro offrent un aperçu de la santé financière actuelle de la société et de ses performances sur le marché.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Avec une capitalisation boursière de 42,34 milliards de dollars, <em>Moderna</em> affiche une présence significative dans le secteur des biotechnologies.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Cette stabilité financière pourrait être cruciale alors que <em>Moderna</em> investit dans le développement de son vaccin contre la grippe en collaboration avec Blackstone Life Sciences et se prépare pour les prochains essais de phase 3 d'autres candidats vaccins.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Les conseils d'InvestingPro soulignent également que la direction de <em>Moderna</em> a activement racheté des actions, ce qui peut refléter la confiance dans l'avenir de l'entreprise et potentiellement soutenir le cours de l'action.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "En outre, alors que les analystes ont revu à la baisse leurs bénéfices pour la période à venir et anticipent une baisse des ventes pour l'année en cours, <em>Moderna</em> a affiché des performances solides au cours du mois dernier, avec un rendement total de 13,45%.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Pour les lecteurs désireux d'approfondir les données financières de <em>Moderna</em> et les prévisions de marché, d'autres Perspectives InvestingPro sont disponibles, offrant un éclairage supplémentaire sur les performances et les perspectives de l'entreprise.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Goldman Sachs réaffirme son opinion d'achat sur l'action <em>Moderna</em>, citant l'accord avec Blackstone Par Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "f813a844-3e19-4544-946e-cdcf8192a2a4",
"title": "Goldman Sachs reiterates Buy on Moderna stock, cites Blackstone deal By Investing.com",
"description": "Goldman Sachs reiterates Buy on Moderna stock, cites Blackstone deal",
"keywords": "",
"snippet": "On Thursday, Goldman Sachs reaffirmed its Buy rating on Moderna (NASDAQ: ) stock, keeping the price target at $206.00. Moderna, listed on NASDAQ:MRNA, recently ...",
"url": "https://www.investing.com/news/company-news/goldman-sachs-reiterates-buy-on-moderna-stock-cites-blackstone-deal-93CH-3356331",
"image_url": "https://i-invdn-com.investing.com/news/Moderna_800x533_L_1608131517.jpg",
"language": "en",
"published_at": "2024-03-28T10:01:54.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 39.793175,
"sentiment_score": 0.20713,
"highlights": [
{
"highlight": "On Thursday, Goldman Sachs reaffirmed its Buy rating on <em>Moderna</em> (NASDAQ: ) stock, keeping the price target at $206.00. <em>Moderna</em>, listed on <em>NASDAQ:MRNA</em>, recently held its fifth Vaccines Day, during which several key updates were shared.",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "This partnership is expected to alleviate some of the R&D costs for <em>Moderna</em>, with returns based on commercial milestones and low-single-digit royalties. A regulatory filing for the flu vaccine is anticipated in 2024.",
"sentiment": -0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "In addition to the Blackstone partnership, <em>Moderna</em> reported positive clinical data from three vaccine candidates that are moving into Phase 3 trials: Epstein-Barr virus, Varicella-Zoster virus, and norovirus.\n\nThe total addressable market for these and other vaccines, excluding respiratory vaccines, is estimated by <em>Moderna</em> to be over $25 billion.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> also provided information on its next-generation COVID-19 vaccine, which is being designed to be stable in a refrigerator.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Overall, Goldman Sachs views the developments as a sign of significant opportunities emerging for <em>Moderna</em> beyond its COVID-19 vaccine, including the individualized neoantigen therapy being developed in partnership with Merck.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "InvestingPro Insights\n\nAs <em>Moderna</em> continues to advance its diverse vaccine portfolio, real-time data from InvestingPro offers a snapshot of the company's current financial health and market performance. With a market capitalization of $42.34 billion, <em>Moderna</em> shows a significant presence in the biotechnology sector.",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "This financial stability could be crucial as <em>Moderna</em> invests in the development of its flu vaccine in collaboration with Blackstone Life Sciences and prepares for upcoming Phase 3 trials of other vaccine candidates.",
"sentiment": -0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "Additionally, while analysts have revised their earnings downwards for the upcoming period and anticipate a sales decline in the current year, <em>Moderna</em> has demonstrated strong returns over the last month with a price total return of 13.45%.",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "To enhance your investment research, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro, where you can find a total of 13 InvestingPro Tips for <em>Moderna</em>.\n\nThis article was generated with the support of AI and reviewed by an editor. For more information see our T&C.",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "Goldman Sachs reiterates Buy on <em>Moderna</em> stock, cites Blackstone deal By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "NASDAQ",
"total_documents": 1658,
"sentiment_avg": 0.28338423383764977
}
]
}
Other details
Country
- us
- 5,275